Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer

10 Sept 2019

Abstract excerpt

Breast cancer is one of the most common malignant cancers affecting females. Estrogen receptor (ER)-positive breast cancer is responsive to endocrine therapy. Although current therapies offer favorable prospects for improving survival, the development of resistance remains a severe problem. In this study, we explored the resistance mechanisms of ER-positive breast cancer to neoadjuvant endocrine therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31506496
DOI: 10.1038/s41598-019-49373-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast CancerPMID 31506496Read ↗

High RAD51 Gene Expression is Associated with Aggressive Biology and with Poor Survival in Breast CancerSemantic proximity Read ↗

Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancerSemantic proximity Read ↗

Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer.Semantic proximity Read ↗

Comprehensive Analysis of the Expression and Prognosis for RAD51 Family in Human Breast CancerSemantic proximity Read ↗

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trialSemantic proximity Read ↗

CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cellsSemantic proximity Read ↗

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response proteinSemantic proximity Read ↗

Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients.Semantic proximity Read ↗

High RAD51 mRNA expression characterize estrogen receptor‐positive/progesteron receptor‐negative breast cancer and is associated with patient's outcomeSemantic proximity Read ↗

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignanciesSemantic proximity Read ↗

A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic PredictionSemantic proximity Read ↗

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.